Novartis to build radioligand therapy plant in Texas

Novartis will build a 46,000-square-foot radioligand therapy site in Denton, Texas. The facility supports a broader expansion to mitigate drug import tariffs.

Xurve View
洞察:

The Swiss drugmaker NOVARTIS AG-2ND LINE[Symbol:{\"assets\":{\"symbol\":\"0QM7.L\"}}] announced on Wednesday its intention to construct a new radioligand therapy (RLT) manufacturing facility in Denton, Texas. This project represents the company's first such facility in Texas and its fifth across the United States[Country:{\"assets\":{\"country\":\"US\"}}].

The logo of Swiss pharmaceutical company Novartis is displayed at its French headquarters in Rueil-Malmaison near Paris, France, in April 2020. REUTERS/Charles Platiau/File Photo
IUX24

IUX24 提供深度財經、經濟與投資資訊,藉助 AI 發掘全球市場中最重要的信號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場數據、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易信號或經紀服務。投資涉及風險,用戶在作出投資決定前應審慎評估相關資訊。